Related Experiment Video
Updated: Dec 23, 2025

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
Psoriasis and Cardiovascular Risk: A Comprehensive Review
Walter Masson1,2, Martín Lobo3, Graciela Molinero3
1Hospital Italiano de Buenos Aires, Perón 4190, C1199ABB, Buenos Aires, Argentina. walter.masson@hospitalitaliano.org.ar.
Insights
Psoriasis patients face higher cardiovascular risks due to systemic inflammation and metabolic issues. Effective cardiovascular risk management is crucial for this population.
Area of Science:
- Immunology
- Dermatology
- Cardiology
Background:
- Psoriasis is a systemic inflammatory disease linked to immune system dysregulation.
- Patients with psoriasis exhibit a higher incidence of cardiovascular disorders.
- Cardiovascular disease risk is elevated in psoriasis patients due to inflammation and metabolic factors.
Purpose of the Study:
- To review evidence linking psoriasis to cardiovascular risk factors and disease.
- To explore pathophysiological mechanisms behind this association.
- To analyze cardiovascular risk stratification and prevention strategies in psoriasis.
Main Methods:
- Epidemiologic and clinical evidence review.
- Analysis of pathophysiological mechanisms.
- Evaluation of cardiovascular prevention therapies and psoriasis medication impact.
Main Results:
- Psoriasis is associated with traditional cardiovascular risk factors and metabolic abnormalities.
- Systemic inflammation and metabolic issues may synergistically increase cardiovascular risk.
- Specific psoriasis treatments may influence cardiovascular risk factors.
Conclusions:
- Understanding the link between psoriasis and cardiovascular disease is vital.
- Comprehensive cardiovascular risk assessment and management are essential for psoriasis patients.
- Targeted prevention strategies can mitigate cardiovascular burden in psoriasis.
Abstract:
Psoriasis is a systemic inflammatory disorder that involves complex pathogenic interactions between the innate and adaptive immune systems. Individuals with psoriasis have an increased risk of developing other chronic health diseases such cardiovascular disorders. The high incidence of cardiovascular events in the population with psoriasis could be explained by several mechanisms. The high prevalence of traditional cardiovascular risk factors and metabolic abnormalities contributes to the high cardiovascular burden in patients with psoriasis. Likewise, the presence of systemic inflammation in combination with metabolic abnormalities may act in a synergistic manner to increase cardiovascular risk in these patients. This review focused on epidemiologic and clinical evidence linking psoriasis to cardiovascular risk factors and cardiovascular disease. We described the possible pathophysiological mechanisms that justify this association and analyzed the best way to stratify the cardiovascular risk in patients with psoriasis. We also described the usefulness of the therapies frequently used in cardiovascular prevention and analyzed the impact of the specific psoriasis medication on cardiovascular risk factors or major atherosclerotic events. Knowledge of the application of different cardiovascular prevention strategies could mean an advantage in performing the difficult task of estimating cardiovascular risk and treating cardiovascular risk factors in this particular group of patients.
Related Concept Videos
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Atherosclerosis III: Management
Coronary Artery Disease I: Introduction
Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease III: Medical Management

